AngioDynamics (ANGO) announced the publication of results from the PRESERVE study in the journal European Urology. The study assessed the safety and effectiveness of irreversible electroporation with the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer. The study met its primary effectiveness endpoint, with 84% of men free from in-field, clinically significant disease at 12 months.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics’ Strong FY25 Performance and Optimistic FY26 Outlook Support Buy Rating
- AngioDynamics initiated with a Buy at Lake Street
- AngioDynamics price target raised to $17 from $15 at Canaccord
- AngioDynamics Reports Strong Growth in Fiscal 2025
- AngioDynamics Reports Strong Growth Amid Challenges